Relay Therapeutics (RLAY) Reports Initial RLY-4008 Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
35% ORR in patients with FGFR2 fusions & 40% ORR in patients with FGFR2-altered HR+/HER2- breast cancer RLY-4008 commercialization plans to focus on broader tumor agnostic opportunities Clinical.